what is the clinical outcome of rhg-csf treatment for neutropenia?
by Nakia Hudson
Published 3 years ago
Updated 3 years ago
Results:In summary, 130 clinical cases treated using PEG-rhG-CSF prophylaxis were included in this study: 51 within the primary prophylaxis (PP) group and 79 within the secondary prophylaxis (SP) group. Compared with SP, PP-based PEG-rhG-CSF successfully contributed to a 14.3% reduction in febrile neutropenia.
Conclusions: PEG-rhG-CSF secondary prevention can effectively reduce the incidence of neutropenia in breast cancer patients receiving adjuvant chemotherapy with EC regimen, which ensures the implementation of standard-dose chemotherapy with good safety.May 25, 2020
Is G-CSF effective in the treatment of cyclic neutropenia?
As the results, 1) Half life of rhG-CSF, 2.87 +/- 0.65 hr, was about 2 times longer than that in healthy subjects, and it was not affected by hemodialysis treatment. 2) Marked increase in leukocyte and neutrophil counts and mild increase in lymphocyte count were observed during single and consecutive administration of rhG-CSF.
When is GM-CSF (sargramostim) indicated in the treatment of neutropenia?
Abstract. This paper outlines the impact of granulocyte-colony stimulating factor (G-CSF) used as a single modality therapy in 17 patients with secondary autoimmune neutropenia (S-AIN) who had been treated a multiple number of times previously. Fifteen of these patients had demonstrable antineutrophil antibodies and two had cellular S-AIN with haemopoietic inhibitory T-cells …
What is the clinical approach to the diagnosis of neutropenia?
Clinical experience with the use of rhG-CSF in secondary autoimmune neutropenia. ... (G-CSF) used as a single modality therapy in 17 patients with secondary autoimmune neutropenia (S-AIN) who had been treated a multiple number of times previously. ... Treatment Outcome; Substances. Autoantibodies; Immunoglobulins, Intravenous;
How much CSF do you give for neutropenia?
The final outcome including death, duration of hospitalization and duration of antibiotics therapy after RhG-CSF administration did not differ between two groups (P>0.05). The results of this study showed that administration of a single dose of RhG-CSF (10 μg/kg) was effective in treating neonatal septicemic neutropenia.
Which CSF may be prescribed to treat neutropenia?
A G-CSF is a drug that doctors prescribe for treating neutropenia. Neutropenia is a condition that causes a person's white blood cell level to drop below normal. White blood cells can drop in people with some types of cancer and those taking certain medications, such as chemotherapy.Mar 18, 2021
What is recombinant CSF used for?
Abstract. Background and objective: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is currently used for treatment of various types of neutropenia, treatment of aplastic anemia, mobilization of peripheral blood progenitor cells.
What is G-CSF used to treat?
G-CSF is used in patients who have certain cancers and neutropenia caused by some types of chemotherapy and in patients who have severe chronic neutropenia that is not caused by cancer treatment. It is also used before an autologous stem cell transplant. G-CSF helps the bone marrow make more white blood cells.
Does G-CSF increased neutrophils?
Further, G-CSF influences the function of mature neutrophils. These actions underpin its rapid uptake into clinical medicine as a drug that increases the production of neutrophils in patients with chemotherapy-induced neutropenia.
How does RhG CSF work?
RhG-CSF-induced effects on neutrophils are well described [5, 15-17]. RhG-CSF stimulates the proliferation of myeloid precursors, accelerates neutrophil release from the bone marrow. It mobilizes secretory vesicles, and induces the release of the contents of specific and azurophilic granules.
What is RhG CSF?
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is currently used for treatment of various types of neutropenia, treatment of aplastic anemia, mobi- lization of peripheral blood progenitor cells.
Why G-CSF is only indicated for some chemotherapy agents?
G-CSF is not needed with all types of chemotherapy. The number of white blood cells usually goes back to a normal level between cycles of chemotherapy. But if white blood cell levels are too low, chemotherapy may have to be delayed or given in a lower dose. G-CSF encourages the bone marrow to make white blood cells.
How long does G-CSF take to work?
This usually takes 5 to 7 days, although it can be longer. If you are having G-CSF before a stem cell transplant, you usually have your first dose 4 to 6 days before your stem cells are going to be collected.
Is G-CSF the same as filgrastim?
Granulocyte - colony stimulating factor (G-CSF) is another name for filgrastim. In some cases, health care professionals may use the trade name Neupogen, Granix or Zarxio when referring to the generic drug name filgrastim.
What is the difference between GM-CSF and G-CSF?
The G-CSF receptor (G-CSFR; CD114) is a homo-oligo-dimer, whereas the GM-CSF receptor (GM-CSFR; CD116) is a hetero-oligo-dimer sharing a β-chain with the IL-3 and IL-5 receptors. The G-CSFR is expressed primarily on neutrophils and bone marrow precursor cells.
What does G-CSF stand for?
G-CSF is a type of growth factor. You might have G-CSF after chemotherapy to help your white blood cells recover after treatment. Or you might have it before and after a stem cell transplant.
What produces G-CSF?
Human G-CSF is produced mainly by monocytes and macrophages (2), but is also produced by fibroblasts (3), endothelial cells (4), and bone marrow stromal cells (5).Feb 19, 2019